查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965889

奧美拉唑市場－全球產業規模、佔有率、趨勢、機會和預測：按最終用途、銷售管道、地區和競爭格局分類，2021-2031年

Omeprazole Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End-Use Application, By Sales Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球奧美拉唑市場預計將從 2025 年的 22,670 噸成長到 2031 年的 31,470 噸，複合年成長率為 5.62%。

奧美拉唑是一種領先的質子幫浦阻斷劑，廣泛用於抑制胃酸分泌，治療胃食道逆流、消化性潰瘍和柔林格症候群等疾病。市場擴張的主要驅動力是全球慢性胃腸道疾病的日益增多，而這些疾病與老化、不良飲食和肥胖等生活方式因素密切相關。高處方率清楚地表明了這種持續的臨床需求。例如，根據英國國家醫療服務體系（NHS）商業服務部門的數據，奧美拉唑將成為2025年英格蘭處方量最大的藥物之一，該財政年度的處方量約為3,600萬劑。

市場概覽
預測期 2027-2031
市場規模：2025年 22,670噸
市場規模：2031年 31470噸
複合年成長率：2026-2031年 5.62%
成長最快的細分市場 胃食道逆流症
最大的市場 北美洲

儘管市場消費量很高，但成長仍面臨一個重大障礙：長期抑酸療法的安全性日益受到關注。越來越多的臨床證據表明，長期使用抑酸藥物與骨折、微量營養素缺乏和腎臟疾病等不良後果有關，這迫使醫療專業人員採取更嚴格的減藥策略。除了這些安全隱患外，來自低成本學名藥的激烈競爭也給該領域的生產商帶來了巨大的產生收入壓力。

市場促進因素

市場成長的主要驅動力是全球胃食道逆流症 (GERD) 和消化性潰瘍盛行率的上升，而這一趨勢主要受生活方式改變的影響。隨著都市化進程的推進，人們的生活方式日益久坐，加工食品的消費量也隨之增加。因此，與肥胖相關的胃腸道疾病激增，這種關聯進一步推高了對抑酸藥物的臨床需求。該患者群體規模龐大，根據美國國立衛生研究院 (NIH) 估計，到 2024 年，全球 GERD 盛行率將達到約 13.98%。此外，代謝健康因素也直接加劇了這項需求。 2024 年 1 月在 ResearchGate 上發表的一項研究題為“肥胖與胃食道逆流的高發病率有關”，發現肥胖人群的 GERD 患病率為 30%，而非肥胖人群的患病率為 24%，這凸顯了因體重相關問題而需要進行治療性介入的必要性。

同時，價格親民的非專利質子幫浦阻斷劑的廣泛市場滲透顯著維持了其收入基礎。專利到期後，低價非專利奧美拉唑的湧現擴大了患者的用藥範圍，使其成為處方藥和非處方藥市場的主力藥。這種實惠的價格確保了患者不會因費用問題而放棄用藥，從而維持了較高的處方量。奧美拉唑的使用量依然龐大；根據ClinCalc的「奧美拉唑－藥物使用統計」資料庫，截至2025年8月，奧美拉唑是美國處方量排名第十的藥物，處方箋超過4,500萬張。如此高的使用率鞏固了其作為標準治療藥物的根深蒂固的地位，同時也確保了其在價格下行壓力下仍能保持穩定的市場表現。

市場挑戰

阻礙全球奧美拉唑市場擴張的關鍵挑戰之一是對長期抑酸治療的安全性監測日益加強。臨床數據顯示，長期使用質子幫浦阻斷劑與骨折、微量營養素缺乏和慢性腎臟病等嚴重不利事件有關，因此醫療機構正積極採用更嚴格的減重藥通訊協定。這種臨床實踐的轉變強調最大限制地減少不必要的藥物使用，並直接限制了以往支撐市場收入的重複處方量。系統性地重新評估長期治療方案將導致處方頻率降低，進而抑制市場成長。

為了佐證下降趨勢，近期數據凸顯了長期不當用藥的普遍性。英國英國全科醫學會2025年的評估發現，約62%接受質子幫浦阻斷劑長期治療的患者並無任何長期用藥的醫學指徵。如此高的不當用藥率迫使醫療委員會和保險公司實施嚴格的停藥政策。因此，隨著醫療系統根據安全指南調整處方行為，製造商面臨銷售大幅下降的局面，這直接降低了該行業的預期成長。

市場趨勢

由於以患者為中心的液體製劑的研發，全球奧美拉唑市場正經歷重大變革。這些液體製劑旨在滿足吞嚥困難的兒童和老年患者的關鍵需求。與傳統的固態劑型不同，這些創新的液體製劑能夠為無法吞嚥膠囊或片劑的患者提供精準的劑量，提高患者的用藥依從性，並在行業內開闢一個專業化的高價值細分市場。這一趨勢的特點是增加對生產能力的投資，以支持確保藥物穩定性的複雜給藥系統。例如，在2024年12月發布的「Alkaloids AD Scopie 2025產業計畫概要」中，該公司預計研發支出將成長10%，以更新產品系列併推動取得專利的高價值藥物的商業化。這其中就包括新推出的即用型液體奧美拉唑。

同時，新型聯合治療的研發正日益受到關注，被視為應對幽門螺旋桿菌感染疾病治療中日益嚴重的抗生素抗藥性的有效手段。製藥商正在開發將奧美拉唑與先進抗生素結合的固定劑量組合藥物，以提高根除率和臨床療效。這種療法超越了單純抑制胃酸分泌的範疇，透過提供全面的治療方法，幫助患者提高用藥依從性，從而在競爭激烈的市場中脫穎而出。這些標靶治療的商業性可行性已透過財務表現得到證實。根據RedHill Biopharma於2025年9月發布的《2025會計年度上半年財務業績報告》，奧美拉唑複方製劑「Talicia」在2025會計年度上半年的淨銷售額達到380萬美元，顯示這些特製製劑正在獲得市場認可。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球奧美拉唑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 最終用途分類（十二指腸潰瘍、胃潰瘍、胃食道逆流、糜爛性食道炎、其他）
    • 銷售管道（直銷、間接銷售）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美奧美拉唑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲奧美拉唑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區奧美拉唑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：奧美拉唑在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：奧美拉唑在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球奧美拉唑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Dr. Reddy's Laboratories Inc
  • Sandoz AG
  • Perrigo Company Plc.
  • Astrazeneca Plc
  • Amneal Pharmaceuticals, Inc
  • Mylan NV
  • Apotex, Inc.
  • Watson Co., Ltd..
  • Santarus Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27399

The Global Omeprazole Market is projected to expand from 22.67 Thousand Tonnes in 2025 to 31.47 Thousand Tonnes by 2031, reflecting a compound annual growth rate of 5.62%. As a prominent proton pump inhibitor, omeprazole is extensively used to inhibit gastric acid secretion for treating ailments like gastroesophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome. Market expansion is chiefly fueled by the increasing prevalence of chronic gastrointestinal conditions worldwide, a trend closely linked to aging demographics and lifestyle choices such as poor diet and obesity. High prescription rates illustrate this sustained clinical need; for example, data from the NHS Business Services Authority indicates that omeprazole was one of England's most dispensed drugs in 2025, with roughly 36 million items distributed during the fiscal year.

Market Overview
Forecast Period2027-2031
Market Size 202522.67 Thousand Tonnes
Market Size 203131.47 Thousand Tonnes
CAGR 2026-20315.62%
Fastest Growing SegmentGastroesophageal Reflux Disease
Largest MarketNorth America

Despite strong consumption levels, market growth faces a notable obstacle in the form of heightened scrutiny regarding the safety of long-term acid suppression therapy. Rising clinical concerns connecting prolonged use with adverse outcomes-such as bone fractures, micronutrient deficiencies, and kidney disease-have compelled healthcare practitioners to adopt more rigorous deprescribing strategies. These safety issues, coupled with fierce competition from low-cost generic substitutes, generate significant pressure on revenue generation for manufacturers operating in this sector.

Market Driver

The primary engine of market growth is the rising global incidence of Gastroesophageal Reflux Disease (GERD) and peptic ulcers, a trend largely shaped by evolving lifestyles. As urbanization accelerates, populations are increasingly adopting sedentary habits and consuming processed foods, resulting in a spike in obesity-associated gastrointestinal conditions. This relationship reinforces the clinical demand for acid suppressants. The scale of this patient population is immense; the National Institutes of Health estimated the global pooled prevalence of GERD at roughly 13.98% in 2024. Moreover, metabolic health factors directly intensify this requirement; a study published on ResearchGate in January 2024, titled 'Obesity is associated with higher prevalence of gastroesophageal reflux disease,' found that obese patients had a 30% GERD prevalence compared to 24% in non-obese individuals, highlighting how weight-related issues necessitate therapeutic intervention.

Simultaneously, the extensive market reach of affordable generic proton pump inhibitors has been fundamental in maintaining revenue streams. Since patent expirations, the availability of low-cost generic omeprazole has broadened access, establishing the drug as a staple in both prescription and over-the-counter markets. This affordability ensures that cost does not impede patient adherence, thereby keeping dispensation rates high. Usage volumes remain substantial; according to the 'Omeprazole - Drug Usage Statistics' database by ClinCalc in August 2025, omeprazole was the tenth most prescribed medication in the United States, with more than 45 million prescriptions written. This frequency confirms the drug's deep-rooted status as a standard of care, securing stable market performance despite downward pricing pressures.

Market Challenge

A pivotal challenge inhibiting the expansion of the Global Omeprazole Market is the intensified scrutiny surrounding the long-term safety of extended acid suppression therapy. As clinical data increasingly associates prolonged proton pump inhibitor use with serious adverse effects like bone fractures, micronutrient deficiencies, and chronic kidney disease, healthcare providers are actively adopting stricter deprescribing protocols. This modification in clinical practice emphasizes minimizing unnecessary medication usage, which directly restricts the volume of repeat prescriptions that have historically underpinned market revenue. The systematic move to re-evaluate long-term therapies necessitates a reduction in dispensing frequency, thereby curbing market growth.

Recent data highlighting the widespread nature of unjustified prolonged usage reinforces this contraction. An evaluation by the Royal College of General Practitioners in 2025 revealed that approximately 62% of patients receiving continuous proton pump inhibitor treatment lacked a recorded medical indication for such extended therapy. This significant rate of inappropriate use compels medical boards and insurers to implement rigorous discontinuation policies. Consequently, manufacturers are encountering a tangible reduction in consumption rates as healthcare systems adjust prescription behaviors to align with safety guidelines, directly diminishing the sector's projected growth.

Market Trends

The Global Omeprazole Market is being significantly transformed by the development of patient-centric liquid formulations designed to meet the critical needs of pediatric and geriatric patients with dysphagia. Unlike conventional solid dosages, these innovative liquid solutions facilitate accurate dosing and enhance adherence for individuals unable to swallow capsules or tablets, establishing a specialized, high-value niche within the industry. This trend is defined by rising investment in production capabilities to support complex delivery systems that ensure drug stability. For example, in the 'ALKALOID AD Skopje 2025 BUSINESS PLAN - SUMMARY' from December 2024, Alkaloid AD Skopje forecasted a 10% increase in R&D expenditure to modernize its portfolio and aid the commercialization of patented value-added medicines, including its newly launched ready-to-use liquid omeprazole.

At the same time, the creation of novel combination therapies is gaining traction as a method to address increasing antibiotic resistance in treating Helicobacter pylori infections. Manufacturers are engineering fixed-dose combinations that integrate omeprazole with advanced antibiotics to boost eradication rates and clinical effectiveness, advancing beyond basic acid suppression. This innovation enables companies to distinguish their offerings in a crowded market by providing comprehensive therapeutic regimens that streamline patient compliance. The commercial viability of these targeted treatments is demonstrated by financial performance; according to the 'RedHill Biopharma Announces First Half 2025 Financial Results' report from September 2025, net revenues for Talicia, an omeprazole-based combination therapy, rose to $3.8 million in the first half of 2025, highlighting the increasing market uptake of these specialized formulations.

Key Market Players

  • Dr. Reddy's Laboratories Inc
  • Sandoz AG
  • Perrigo Company Plc.
  • Astrazeneca Plc
  • Amneal Pharmaceuticals, Inc
  • Mylan N.V.
  • Apotex, Inc.
  • Watson Co., Ltd..
  • Santarus Inc.

Report Scope

In this report, the Global Omeprazole Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omeprazole Market, By End-Use Application

  • Duodenal Ulcer
  • Gastric Ulcer
  • Gastroesophageal Reflux Disease
  • Erosive Esophagitis
  • Others

Omeprazole Market, By Sales Channel

  • Direct Sale
  • Indirect Sale

Omeprazole Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omeprazole Market.

Available Customizations:

Global Omeprazole Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omeprazole Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By End-Use Application (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease, Erosive Esophagitis, Others)
    • 5.2.2. By Sales Channel (Direct Sale, Indirect Sale)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Omeprazole Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By End-Use Application
    • 6.2.2. By Sales Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omeprazole Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By End-Use Application
        • 6.3.1.2.2. By Sales Channel
    • 6.3.2. Canada Omeprazole Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By End-Use Application
        • 6.3.2.2.2. By Sales Channel
    • 6.3.3. Mexico Omeprazole Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By End-Use Application
        • 6.3.3.2.2. By Sales Channel

7. Europe Omeprazole Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By End-Use Application
    • 7.2.2. By Sales Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Omeprazole Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By End-Use Application
        • 7.3.1.2.2. By Sales Channel
    • 7.3.2. France Omeprazole Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By End-Use Application
        • 7.3.2.2.2. By Sales Channel
    • 7.3.3. United Kingdom Omeprazole Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By End-Use Application
        • 7.3.3.2.2. By Sales Channel
    • 7.3.4. Italy Omeprazole Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By End-Use Application
        • 7.3.4.2.2. By Sales Channel
    • 7.3.5. Spain Omeprazole Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By End-Use Application
        • 7.3.5.2.2. By Sales Channel

8. Asia Pacific Omeprazole Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By End-Use Application
    • 8.2.2. By Sales Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Omeprazole Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By End-Use Application
        • 8.3.1.2.2. By Sales Channel
    • 8.3.2. India Omeprazole Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By End-Use Application
        • 8.3.2.2.2. By Sales Channel
    • 8.3.3. Japan Omeprazole Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By End-Use Application
        • 8.3.3.2.2. By Sales Channel
    • 8.3.4. South Korea Omeprazole Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By End-Use Application
        • 8.3.4.2.2. By Sales Channel
    • 8.3.5. Australia Omeprazole Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By End-Use Application
        • 8.3.5.2.2. By Sales Channel

9. Middle East & Africa Omeprazole Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By End-Use Application
    • 9.2.2. By Sales Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Omeprazole Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By End-Use Application
        • 9.3.1.2.2. By Sales Channel
    • 9.3.2. UAE Omeprazole Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By End-Use Application
        • 9.3.2.2.2. By Sales Channel
    • 9.3.3. South Africa Omeprazole Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By End-Use Application
        • 9.3.3.2.2. By Sales Channel

10. South America Omeprazole Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By End-Use Application
    • 10.2.2. By Sales Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Omeprazole Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By End-Use Application
        • 10.3.1.2.2. By Sales Channel
    • 10.3.2. Colombia Omeprazole Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By End-Use Application
        • 10.3.2.2.2. By Sales Channel
    • 10.3.3. Argentina Omeprazole Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By End-Use Application
        • 10.3.3.2.2. By Sales Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Omeprazole Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dr. Reddy's Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sandoz AG
  • 15.3. Perrigo Company Plc.
  • 15.4. Astrazeneca Plc
  • 15.5. Amneal Pharmaceuticals, Inc
  • 15.6. Mylan N.V.
  • 15.7. Apotex, Inc.
  • 15.8. Watson Co., Ltd..
  • 15.9. Santarus Inc.

16. Strategic Recommendations

17. About Us & Disclaimer